NAMS·N62509109·US·equity·Healthcare - Biotechnology-Activist
ORDINARY SHARES
NAMS (NEWAMSTERDAM PHARMA COMPANY) is held by 91 institutional investors as of Q1 2026. Largest holders: Capital World Investors ($355.6M), RA CAPITAL MANAGEMENT, L.P. ($305.7M), FMR LLC ($280.6M). Net institutional sentiment: Mixed.
See how NAMS's score breaks down across 4 SEC sources
Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer